Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avra Laboratories Gets Regulatory Approval for Covid-19 Drug Favipiravir
Details : Ciplenza (favipiravir-generic) is a RNA-directed RNA polymerase inhibitor, small molecule, which is indicated for the treatment of patients with Covid-19 infection.
Brand Name : Ciplenza
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 27, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
KEY PRODUCTS
Reset All
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.